**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 59491

**Manuscript Type:** CASE REPORT

**Coinheritance of *OLFM2* and *SIX6* variants in a Chinese family with juvenile-onset primary open-angle glaucoma: A case report**

Yang X *et al*. *OLFM2* and *SIX6* variants in primary open-angle glaucoma

Xue Yang, Nan-Nan Sun, Zhen-Ni Zhao, Shu-Xiang He, Miao Zhang, Dan-Dan Zhang, Xiao-Wei Yu, Jia-Min Zhang, Zhi-Gang Fan

**Xue Yang, Nan-Nan Sun, Zhen-Ni Zhao, Miao Zhang, Dan-Dan Zhang, Xiao-Wei Yu, Jia-Min Zhang, Zhi-Gang Fan,** State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China

**Shu-Xiang He,** Guangzhou KingMed Diagnostics Group Co., Ltd, Guangzhou 510060, Guangdong Province, China

**Author contributions:** Fan ZG conceived and designed the study; Zhang M, Yu XW and Zhang JM performed the experiments; Yang X, Zhao ZN and Zhang DD provided clinical research; Yang X and Sun NN wrote the manuscript; Yang X, Sun NN, He SX and Fan ZG reviewed and edited the manuscript; all authors read and approved the manuscript.

**Supported by** theGuangzhou Science and Technology Plan Project, No. 201803040020 and 201903010065; the Guangdong Natural Science Foundation, No. 2020A1515010168; and the Research Funds of the State Key Laboratory of Ophthalmology, No. PT1001022.

**Correspondence to: Zhi-Gang Fan, MD, PhD, Professor, Chief Doctor,** State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, No. 7 Jinsui Road, Tianhe District, Guangzhou 510060, Guangdong Province, China. fanzhg3@mail.sysu.edu.cn

**Received:** September 14, 2020

**Revised:** November 26, 2020

**Accepted:** December 6, 2020

**Published online:** January 26, 2021

**Abstract**

BACKGROUND

Juvenile-onset primary open-angle glaucoma (JOAG), characterized by severe elevation of intraocular pressure and optic neuropathy prior to the age of 40, is a rare subtype of primary open-angle glaucoma. Several genetic mutations have been associated with JOAG.

CASE SUMMARY

The proband patient was a young male, diagnosed with primary open-angle glaucoma at the age of 27. The patient and his unaffected parents who have been excluded from classic genetic mutations for primary open-angle glaucoma were included to explore for other possible genetic variants through whole genome sequencing and bioinformatics analysis.In this trio, we found two heterozygous variants inherited from the parents in the proband: c.281G>A, p.Arg94His in *OLFM2* and c.177C>G, p.Ile59Met in *SIX6*. Both genetic mutations are predicted through bioinformatics analysis to replace evolutionary conserved amino acids, therefore rendering a pathogenic effect on proteins. In contrast, very low frequencies for these genetic mutations were recorded in most common control databases.

CONCLUSION

This is the first report on coinherited mutations of *OLFM2* and *SIX6* in a JOAG family, which shows the complexity of JOAG inheritance. Large-scale clinical screening and molecular functional investigations on these coinherited mutations are imperative to improve our understanding of the development of JOAG.

**Key Words:** Juvenile-onset primary open-angle glaucoma; Whole genome sequencing; Co-inheritance; *OLFM2*; *SIX6*; Case report

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yang X, Sun NN, Zhao ZN, He SX, Zhang M, Zhang DD, Yu XW, Zhang JM, Fan ZG. Coinheritance of *OLFM2* and *SIX6* variants in a Chinese family with juvenile-onset primary open-angle glaucoma: A case report. *World J Clin Cases* 2021; 9(3): 697-706

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i3/697.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i3.697

**Core Tip:** This report describes a case of juvenile-onset primary open-angle glaucoma (JOAG) with a coinheritance of *OLFM2* and *SIX6* variants, which might contribute to the onset of JOAG. This finding may enrich the genetic spectrum of JOAG and prompt us to further investigate the functional effects of the two variants on JOAG.

**INTRODUCTION**

Primary open-angle glaucoma (POAG) is a group of polygenic heterogeneous diseases, with characteristic glaucomatous optic neuropathy and visual-field defects. POAG is the second most common cause of irreversible blindness worldwide[1]. Juvenile-onset primary open-angle glaucoma (JOAG) is a unique subtype of POAG, characterized by an early disease onset prior to 40-years-old, usually a significantly elevated intraocular pressure (IOP) and severe glaucomatous optic neuropathy[2]. JOAG progresses more rapidly in comparison with classic adult-onset POAG[3].

POAG is essentially a neurodegenerative disease in the elderly population[4], whose onset is determined by interactions between various environmental and genetic factors. JOAG, due to its early onset, is likely subsequent to a genetic mutation. Currently, several genes, including *MYOC*, *OPTN*, *CYP1B1*, *OAS3*, *PITX2* and *LTBP2* have been reported to be associated with JOAG[5-7] through traditional Mendel genetic analysis. However, clinically there are still many JOAG cases that cannot be attributed to these reported genetic mutations. Therefore, a strategy using whole genome sequencing (WGS) and *de novo* mutation trio analysis[8] can be used to explore novel genetic variants.

In this current study, we performed WGS on a trio (the proband and his unaffected parents) at Zhongshan Ophthalmic Center to identify potential disease-causing mutations. After excluding classic glaucoma-associated gene mutations, we surprisingly found two heterozygous gene variants that were predicted to be potentially pathogenic *via* bioinformatics analysis in the proband. To our knowledge, this is the first report on a JOAG family that has been associated with a coinheritance of *OLFM2* (c.281G>A, p.Arg94His) and *SIX6* (c.177C>G, p.Ile59Met) variants.

**CASE PRESENTATION**

***Chief complaints***

A 27-year-old male was admitted to our hospital due to elevated IOP of both eyes for nearly 3 mo.

***History of present illness***

There was no relevant ocular or medical history.

***History of past illness***

The patient was previously diagnosed with myopia, and he was allergic to cefradine. No history of systemic hypertension, diabetes mellitus, coronary heart disease, stroke, smoking or obesity was reported.

***Personal and family history***

There was no remarkable personal and family history.

***Physical examination***

His myopic refractive error at -3.00 diopter of both eyes was detected. The IOPs without prescription medications at the initial visit in Zhongshan Ophthalmic Center were 28.7 mmHg in the right eye and 31.4 mmHg in the left eye, which was recorded as the peak IOP. Best corrected visual acuity was 1.0 in each eye measured by the standard Snellen chart.

***Laboratory examinations***

Routine blood examination, liver and kidney function and electrolyte test indicators were normal.

***Imaging examinations***

Fundus examination with color photos was accomplished with particular attention paid to make sure that image focus was exactly on the optic disk margins. The result showed vertical cup disc ratio of his right eye was 0.7 and his left eye was 0.8 with localized cupping in both eyes. A localized retinal nerve fiber layer thinning corresponding to the optic disc cupping was detected by Heidelberg Spectralis optical coherence tomography (Heidelberg Engineering, Heidelberg, Germany) in each eye, with an average retinal nerve fiber layer thickness significantly reduced at 69 µm oculusdexterand 67 µm oculus sinister. Visual field defects were detected by Humphrey Visual Field Analyzer (Zeiss Meditech, Jena, Germany) in both eyes with the visual field mean deviation of -6.75 dB oculusdexter and -5.30 dB oculus sinister (Figure 1).

***Further diagnostic work-up***

**WGS:** WGS followed the same protocol as previously reported[9]. The sequencing depth among participants ranged from 54.23X to 60.27X, with the percentage of coverage more than 10X at 91.53% to 92.20%. Mutations identified were analyzed using an autosomal recessive model as well as *de novo* dominant model. We have excluded mutations with a minor allele frequency more than 0.1% in either the Genome Aggregation Database or the Exome Aggregation Consortium. According to the data from the Human Phenotype Ontology, the names of the reference genes screened are listed in the Supplementary Table 1. The screening criteria for deleterious mutations were based on the American College of Medical Genetics guidelines[10]. In trio-based WGS, the single nucleotide polymorphism in some of the major gene loci (Supplementary Table 2) that were previously reported to affect JOAG phenotype, such as *MYOC* and *LTBP2*[6,7] as well as *de novo* dominant mutations were not detected. Importantly, it was found that the proband (II1) had coinherited mutations. The proband has a c.281G>A, p.Arg94His in *OLFM2* (NM\_058164.3) inherited from his father (I1) and a c.177C>G, p.Ile59Met in *SIX6* (NM\_007374.2) inherited from his mother (I2), which cosegregates with the phenotype in a recessive pattern (Figure 2). Interestingly, the *OLFM2* mutation from the father is also transmitted to another sibling (II2), who is exempt from any glaucoma phenotypes. The *OLFM2* mutation (c.281G>A, p.Arg94His) had a minor allele frequency of 0.005% in the Exome Aggregation Consortium and 0.004% in the Genome Aggregation Database, while the specific mutation was classified as deleterious in MutationTaster, mCAP and CADD. The *SIX6* mutation (c.177C>G, p.Ile59Met) was absent in the Exome Aggregation Consortium and had a minor allele frequency of 0.0004% in the Genome Aggregation Database, which was classified as deleterious in MutationTaster, Fathmm and mCAP. Importantly, these mutations were found to be highly conserved across various species (Figure 3).

**Sanger sequencing:** Amplification using PCR followed by Sanger sequencing was used to confirm the identified mutations of *OLFM2* and *SIX6* in each family member. Sequencing was performed on an ABI 3730xl DNA analyzer (Applied Biosystems, Foster City, CA, United States). The reference genes were obtained from the Ensembl genome browser (in the public domain, http://www.ensembl.org). The primers used for PCR amplification are listed in Table 1.

**FINAL DIAGNOSIS**

JOAG in both eyes.

**TREATMENT**

Since the diagnosis of glaucoma, the patient has been routinely treated with medication (brimonidine tartrate eye drops, three times a day; travatan, *quaque nocte*; azopt, twice a day) to control IOP for more than 3 mo. At the age of 28, the patient received an express implant (Glaucoma Filtration Device Version P-200) in the right eye. One month later, his left eye was also treated with an express implant (Glaucoma Filtration Device Version P-200). Antibiotic eye drops (compound neomycin sulfate) and eye ointment (tobramycin dexamethasone) were used for anti-inflammation postoperatively.

**OUTCOME AND FOLLOW-UP**

The IOPs were well controlled at middle 10 s in both eyes postoperatively and during regular follow-up.

**DISCUSSION**

JOAG is a rare subtype of POAG that is closely associated with genetic mutations. In the present study, we have for the first time, reported a coinheritance of mutations in *OLFM2* (c.281G>A, p.Arg94His) and *SIX6* (c.177C>G, p.Ile59Met) in a patient with JOAG through WGS and bioinformatics analysis. The potentially pathogenic mutations in *OLFM2* and *SIX6*, inherited from the father and the mother, respectively, might be responsible for the onset of JOAG in this proband. Digenic inheritance is the simplest form for genetically complex diseases. By contrast with the thousands of reports that mutations in single genes cause human diseases, there are many human disease phenotypes with evidence for digenic inheritance in some pedigrees. Therefore, whether the inherited pattern of the proband is consistent with digenic inheritance needs to be further verified through functional research. Our report of coinherited *OLFM2* and *SIX6* variants in a JOAG family indicates the complexity of JOAG inheritance and enriches our understanding of the mutation spectrum in JOAG.

*OLFM2* encodes a secreted glycoprotein in the Noelin family of olfactomedin domain-containing proteins that regulate the timing of neuronal differentiation during development[11]. The olfactomedin domain-containing protein that has been studied most comprehensively is myocilin encoded by the *MYOC* gene. Through phylogenetic analysis in humans, it was suggested that *MYOC* may have evolved from *OLFM2* through gene duplication followed by exon fusion, which may partially explain a 31% homology between *MYOC* and *OLFM2*[12]. *MYOC* is the first candidate gene mapped for POAG. Mutations in *MYOC* account for 4%-35% of adult-onset POAG and for more than 10% in JOAG[12-14]. Therefore, it is reasonable to speculate that certain mutations in *OLFM2* may also have detrimental effects in the development of JOAG. Funayama *et al*[15] reported that the Arg144Gln (exon 4) mutation in *OLFM2* might result in POAG in Japanese patients. They also found that the combination of single nucleotide polymorphisms in *OLFM2/317G* and *OPTN/603A* was significantly associated with IOP elevation. However, their data were derived from sporadic case analysis, and there was no genetic information based on family inheritance. The origin of disease-causing mutations was unknown.

Loss of retinal ganglion cells (RGCs) and their axons are the primary diagnostic pathology in glaucoma. We have long known that the retina and optic nerve are embryonically and structurally part of the brain. Numerous studies have attempted to establish connections between glaucoma and neurodegeneration in the brain[16,17]. Previously, it was reported that *OLFM2* was mainly expressed in the olfactory bulb, cortex, piriform cortex, olfactory trabeculae and inferior and superior colliculus in the brain. Functional investigation using *Olfm2*-KOLacZ mice demonstrated that the loss of *Olfm2* caused a reduction of synaptic proteins in the brain and the retina[18]. Although not systemically investigated, the impairment of synaptic connections between neurons within the retina and the brain can potentially affect structural and functional integrity of RGCs and their axons. Interestingly, it was shown that genetic mutant *Olfm2* inmouse was associated with abnormal psychological phenotypes such as anxiety and reduced levels of exploratory and locomotor activities[18], while ours and various other studies have shown that psychological conditions such as anxiety are strongly connected with the incidence of POAG[19-21] likely through reduced retrograde axonal transport of neurotropic factors, such as brain-derived neurotrophic factor. Taken together, *OLFM2* is likely a candidate gene for POAG/JOAG.

*SIX6* is also known as *OPTX2*, which belongs to the SIX/Sine oculis homeobox family that covers 1 homeobox DNA-binding domain. Various reports on pathogenic mutations in *SIX6* have been connected to POAG. The connection between single nucleotide polymorphisms (rs33912345, rs10483727 and rs12436579) in *SIX6* and POAG was established by genome-wide association studies[22,23]. Another study including POAG patients with missense variant in *SIX6* (rs33912345) showed that a smaller optic disc rim area, larger vertical cup-disc ratio and significantly decreased average nerve fiber layer thickness are detected in patients with homozygous mutations in contrast to those with the nonrisk allele[24,25]. It was found in another study that clinical features in POAG patients appear to be dependent on the *SIX6* genotype[26].

In our study, we found two missense mutations in *OLFM2* (c.281G>A, p.Arg94His) and *SIX6* (c.177C>G, p.Ile59Met) by WGS in a trio. Interestingly, the proband with JOAG coinherited one mutation from each parent. Furthermore, we included another nine trios with a JOAG proband and unaffected parents to verify the deleterious mutations. However, we did not find any duplicate cases due to an insufficient number of trios. Nevertheless, combined with various functional studies on *OLFM2* and *SIX6* mutations, we still suspected the coinherited variants might contribute to occurrence of JOAG. Based on data from the FANTOM5 dataset[27,28], *OLFM2* and *SIX6* are both expressed in the human retina. In mice, *OLFM2* is mainly detected in RGC[18]. In an *in vitro* disease model using the *SIX6* risk allele (rs33912345; C>A; His141Asn) carrying glaucoma patient-specific induced pluripotent stem cells for functional RGC regeneration, it was demonstrated that the number of RGCs generated was decreased and the expression of RGC regulatory genes were suppressed by altered *SIX6* function[29]. In *Olfm2*-KOLacZ mice, the primary wave at the visual cortex in visual evoked potential was found to be significantly reduced when compared with those in wild-type littermates. A slight reduction in the number of RGCs and their axons was also observed in the *Olfm2*-KOLacZ mice. In zebrafish, it was found that *Olfm2*-KO retarded nervous system development[30]. Additionally, loss of *SIX6* in early development may cause small eye phenotype, under-development of the lens and reduced neural fiber layer around the optic nerve head[26]. There are clinical studies in which patients with anophthalmia and microphthalmia were found to have *SIX6* mutations[31]. Significantly, mutations in *OLFM2* can alsoresult in anophthalmia, microphthalmia and coloboma[32], which altogether indicate that *OLFM2* and *SIX6* may have interactions working together in shaping eyedevelopment. We hypothesize that *OLFM2* and *SIX6* genes and their proteinproducts may interact to regulate a critical pathway in ocular development, which if disturbed may lead to the pathogenesis of JOAG/POAG.

To date, there are only two reports on glaucoma that have shown clear evidence for digenic inheritance[33,34]. In primary congenital glaucoma, *LTBP2* p.R299X homozygous mutation plus *CYP1B1* p.E387K heterozygous mutation resulted in a severe clinical phenotype and poor prognosis[33]. Carriers of both the *MYOC* and *CYP1B1* mutations lead to POAG at an earlier age (27-years-old) compared with carriers of only the *MYOC* mutation (51-years-old)[34]. These data indicate that coinherited mutations may play an important role in determining the age of disease onset. Under this situation, one genetic mutation may work as a “dominator” while the other functions as a “regulator”. Therefore, a conservative approach to counselling may be warranted, under the assumption that some *SIX6* mutations may render susceptibility but are not sufficient to cause glaucoma. The existence of another genetic mutation, for example, *OLFM2*, may facilitate a pathogenic effect of *SIX6* mutations. To investigate our hypothesis, functional work on the association between *OLFM2* and *SIX6* should be carried out in the future.

**CONCLUSION**

In summary, we identified a coinheritance of *OLFM2* and *SIX6* variants in a core family of JOAG through WGS, Sanger sequencing and bioinformatics analysis. This specific inheritance would not have been identified through traditional Mendelian inheritance studies or analysis with a gene chip-based test. WGS covering a great number of annotated exons was the best option for finding novel mutations. It should be emphasized that a WGS strategy on trios is crucial for further genetic studies in JOAG/POAG. Additionally, previous families investigated by Mendelian inheritance should be further explored with a WGS approach. JOAG/POAG is a group of polygenic heterogeneous disease in which a single genetic mutation may not be sufficient to cause a clinical phenotype. Genetic mutations from digenic or polygenic inheritance may result in pathogenesis changes that are beyond physiological compensation. Large-scale clinical screening and molecular functional investigations into the association of this coinherited *OLFM2* and *SIX6* variants are imperative to enrich our understanding on the pathogenesis of JOAG/POAG.

**ACKNOWLEDGEMENTS**

The authors would like to thank all participants for providing blood samples and agreeing to participate in this research.

**REFERENCES**

1 **Jonas JB**, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. *Lancet* 2017; **390**: 2183-2193 [PMID: 28577860 DOI: 10.1016/S0140-6736(17)31469-1]

2 **Turalba AV**, Chen TC. Clinical and genetic characteristics of primary juvenile-onset open-angle glaucoma (JOAG). *Semin Ophthalmol* 2008; **23**: 19-25 [PMID: 18214788 DOI: 10.1080/08820530701745199]

3 **Kwun Y**, Lee EJ, Han JC, Kee C. Clinical Characteristics of Juvenile-onset Open Angle Glaucoma. *Korean J Ophthalmol* 2016; **30**: 127-133 [PMID: 27051261 DOI: 10.3341/kjo.2016.30.2.127]

4 **Weinreb RN**, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, Martin KR. Primary open-angle glaucoma. *Nat Rev Dis Primers* 2016; **2**: 16067 [PMID: 27654570 DOI: 10.1038/nrdp.2016.67]

5 **Wax MB**, Tezel G, Yang J, Peng G, Patil RV, Agarwal N, Sappington RM, Calkins DJ. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. *J Neurosci* 2008; **28**: 12085-12096 [PMID: 19005073 DOI: 10.1523/JNEUROSCI.3200-08.2008]

6 **Huang C**, Xie L, Wu Z, Cao Y, Zheng Y, Pang CP, Zhang M. Detection of mutations in MYOC, OPTN, NTF4, WDR36 and CYP1B1 in Chinese juvenile onset open-angle glaucoma using exome sequencing. *Sci Rep* 2018; **8**: 4498 [PMID: 29540704 DOI: 10.1038/s41598-018-22337-2]

7 **Saeedi O**, Yousaf S, Tsai J, Palmer K, Riazuddin S, Ahmed ZM. Delineation of Novel Compound Heterozygous Variants in LTBP2 Associated with Juvenile Open Angle Glaucoma. *Genes* (Basel) 2018; **9**: 527 [PMID: 30380740 DOI: 10.3390/genes9110527]

8 **Jiang YH**, Yuen RK, Jin X, Wang M, Chen N, Wu X, Ju J, Mei J, Shi Y, He M, Wang G, Liang J, Wang Z, Cao D, Carter MT, Chrysler C, Drmic IE, Howe JL, Lau L, Marshall CR, Merico D, Nalpathamkalam T, Thiruvahindrapuram B, Thompson A, Uddin M, Walker S, Luo J, Anagnostou E, Zwaigenbaum L, Ring RH, Wang J, Lajonchere C, Wang J, Shih A, Szatmari P, Yang H, Dawson G, Li Y, Scherer SW. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. *Am J Hum Genet* 2013; **93**: 249-263 [PMID: 23849776 DOI: 10.1016/j.ajhg.2013.06.012]

9 **Guo C**, Zhao Z, Chen D, He S, Sun N, Li Z, Liu J, Zhang D, Zhang J, Li J, Zhang M, Ge J, Liu X, Zhang X, Fan Z. Detection of Clinically Relevant Genetic Variants in Chinese Patients With Nanophthalmos by Trio-Based Whole-Genome Sequencing Study. *Invest Ophthalmol Vis Sci* 2019; **60**: 2904-2913 [PMID: 31266062 DOI: 10.1167/iovs.18-26275]

10 **Richards S**, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**: 405-424 [PMID: 25741868 DOI: 10.1038/gim.2015.30]

11 **Davies GS**, Cohen J. In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance. *J Antimicrob Chemother* 1985; **16**: 713-717 [PMID: 2936706 DOI: 10.1007/s12035-009-8076-x]

12 **Sultana A**, Nakaya N, Senatorov VV, Tomarev SI. Olfactomedin 2: expression in the eye and interaction with other olfactomedin domain-containing proteins. *Invest Ophthalmol Vis Sci* 2011; **52**: 2584-2592 [PMID: 21228389 DOI: 10.1167/iovs.10-6356]

13 **Sears NC**, Boese EA, Miller MA, Fingert JH. Mendelian genes in primary open angle glaucoma. *Exp Eye Res* 2019; **186**: 107702 [PMID: 31238079 DOI: 10.1016/j.exer.2019.107702]

14 **Li Q**, Liu A, Gu X, Su Z. Olfactomedin domain-containing proteins: evolution, functional divergence, expression patterns and damaging SNPs. *Mol Genet Genomics* 2019; **294**: 875-885 [PMID: 30915543 DOI: 10.1007/s00438-019-01549-9]

15 **Funayama T**, Mashima Y, Ohtake Y, Ishikawa K, Fuse N, Yasuda N, Fukuchi T, Murakami A, Hotta Y, Shimada N; Glaucoma Gene Research Group. SNPs and interaction analyses of noelin 2, myocilin, and optineurin genes in Japanese patients with open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2006; **47**: 5368-5375 [PMID: 17122126 DOI: 10.1167/iovs.06-0196]

16 **Mélik Parsadaniantz S**, Réaux-le Goazigo A, Sapienza A, Habas C, Baudouin C. Glaucoma: A Degenerative Optic Neuropathy Related to Neuroinflammation? *Cells* 2020; **9**: 535 [PMID: 32106630 DOI: 10.3390/cells9030535]

17 **Williams PA**, Marsh-Armstrong N, Howell GR; Lasker/IRRF Initiative on Astrocytes and Glaucomatous Neurodegeneration Participants. Neuroinflammation in glaucoma: A new opportunity. *Exp Eye Res* 2017; **157**: 20-27 [PMID: 28242160 DOI: 10.1016/j.exer.2017.02.014]

18 **Sultana A**, Nakaya N, Dong L, Abu-Asab M, Qian H, Tomarev SI. Deletion of olfactomedin 2 induces changes in the AMPA receptor complex and impairs visual, olfactory, and motor functions in mice. *Exp Neurol* 2014; **261**: 802-811 [PMID: 25218043 DOI: 10.1016/j.expneurol.2014.09.002]

19 **Zhang D**, Fan Z, Gao X, Huang W, Yang Q, Li Z, Lin M, Xiao H, Ge J. Illness uncertainty, anxiety and depression in Chinese patients with glaucoma or cataract. *Sci Rep* 2018; **8**: 11671 [PMID: 30076311 DOI: 10.1038/s41598-018-29489-1]

20 **Zhang X**, Olson DJ, Le P, Lin FC, Fleischman D, Davis RM. The Association Between Glaucoma, Anxiety, and Depression in a Large Population. *Am J Ophthalmol* 2017; **183**: 37-41 [PMID: 28760639 DOI: 10.1016/j.ajo.2017.07.021]

21 **Rezapour J**, Nickels S, Schuster AK, Michal M, Münzel T, Wild PS, Schmidtmann I, Lackner K, Schulz A, Pfeiffer N, Beutel ME. Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study. *BMC Ophthalmol* 2018; **18**: 157 [PMID: 29954361 DOI: 10.1186/s12886-018-0831-1]

22 **Rong SS**, Lu SY, Matsushita K, Huang C, Leung CKS, Kawashima R, Usui S, Tam POS, Young AL, Tsujikawa M, Zhang M, Nishida K, Wiggs JL, Tham CC, Pang CP, Chen LJ. Association of the SIX6 locus with primary open angle glaucoma in southern Chinese and Japanese. *Exp Eye Res* 2019; **180**: 129-136 [PMID: 30586556 DOI: 10.1016/j.exer.2018.12.014]

23 **Kondkar AA**, Azad TA, Almobarak FA, Kalantan H, Sultan T, Alsabaani NA, Al-Obeidan SA, Abu-Amero KK. Polymorphism rs10483727 in the SIX1/SIX6 Gene Locus Is a Risk Factor for Primary Open Angle Glaucoma in a Saudi Cohort. *Genet Test Mol Biomarkers* 2018; **22**: 74-78 [PMID: 29190129 DOI: 10.1089/gtmb.2017.0159]

24 **Khawaja AP**, Chan MPY, Yip JLY, Broadway DC, Garway-Heath DF, Viswanathan AC, Luben R, Hayat S, Hauser MA, Wareham NJ, Khaw KT, Fortune B, Allingham RR, Foster PJ. A Common Glaucoma-risk Variant of SIX6 Alters Retinal Nerve Fiber Layer and Optic Disc Measures in a European Population: The EPIC-Norfolk Eye Study. *J Glaucoma* 2018; **27**: 743-749 [PMID: 30005032 DOI: 10.1097/IJG.0000000000001026]

25 **Yariz KO**, Sakalar YB, Jin X, Hertz J, Sener EF, Akay H, Özbek MN, Farooq A, Goldberg J, Tekin M. A homozygous SIX6 mutation is associated with optic disc anomalies and macular atrophy and reduces retinal ganglion cell differentiation. *Clin Genet* 2015; **87**: 192-195 [PMID: 24702266 DOI: 10.1111/cge.12374]

26 **Carnes MU**, Liu YP, Allingham RR, Whigham BT, Havens S, Garrett ME, Qiao C; NEIGHBORHOOD Consortium Investigators, Katsanis N, Wiggs JL, Pasquale LR, Ashley-Koch A, Oh EC, Hauser MA. Discovery and functional annotation of SIX6 variants in primary open-angle glaucoma. *PLoS Genet* 2014; **10**: e1004372 [PMID: 24875647 DOI: 10.1371/journal.pgen.1004372]

27 **Crisci V**, Orso CA. [Involvement and paralysis of the ulnar nerve in elbow arthrosis]. *Minerva Ortop* 1968; **19**: 570-577 [PMID: 4310165 DOI: 10.1186/s13059-014-0560-6]

28 **Nishimura SL**, Recht LD, Pasternak GW. Biochemical characterization of high-affinity 3H-opioid binding. Further evidence for Mu1 sites. *Mol Pharmacol* 1984; **25**: 29-37 [PMID: 6323950 DOI: 10.1093/nar/gky1099]

29 **Teotia P**, Van Hook MJ, Wichman CS, Allingham RR, Hauser MA, Ahmad I. Modeling Glaucoma: Retinal Ganglion Cells Generated from Induced Pluripotent Stem Cells of Patients with SIX6 Risk Allele Show Developmental Abnormalities. *Stem Cells* 2017; **35**: 2239-2252 [PMID: 28792678 DOI: 10.1002/stem.2675]

30 **Lee JA**, Anholt RR, Cole GJ. Olfactomedin-2 mediates development of the anterior central nervous system and head structures in zebrafish. *Mech Dev* 2008; **125**: 167-181 [PMID: 18037275 DOI: 10.1016/j.mod.2007.09.009]

31 **Aldahmesh MA**, Khan AO, Hijazi H, Alkuraya FS. Homozygous truncation of SIX6 causes complex microphthalmia in humans. *Clin Genet* 2013; **84**: 198-199 [PMID: 23167593 DOI: 10.1111/cge.12046]

32 **Holt R**, Ugur Iseri SA, Wyatt AW, Bax DA, Gold Diaz D, Santos C, Broadgate S, Dunn R, Bruty J, Wallis Y, McMullan D, Ogilvie C, Gerrelli D, Zhang Y, Ragge N. Identification and functional characterisation of genetic variants in OLFM2 in children with developmental eye disorders. *Hum Genet* 2017; **136**: 119-127 [PMID: 27844144 DOI: 10.1007/s00439-016-1745-8]

33 **Azmanov DN**, Dimitrova S, Florez L, Cherninkova S, Draganov D, Morar B, Saat R, Juan M, Arostegui JI, Ganguly S, Soodyall H, Chakrabarti S, Padh H, López-Nevot MA, Chernodrinska V, Anguelov B, Majumder P, Angelova L, Kaneva R, Mackey DA, Tournev I, Kalaydjieva L. LTBP2 and CYP1B1 mutations and associated ocular phenotypes in the Roma/Gypsy founder population. *Eur J Hum Genet* 2011; **19**: 326-333 [PMID: 21081970 DOI: 10.1038/ejhg.2010.181]

34 **Vincent AL**, Billingsley G, Buys Y, Levin AV, Priston M, Trope G, Williams-Lyn D, Héon E. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. *Am J Hum Genet* 2002; **70**: 448-460 [PMID: 11774072 DOI: 10.1086/338709]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 14, 2020

**First decision:** November 20, 2020

**Article in press:** December 6, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Byeon H, Demir AB, Vunnam RR **S-Editor:** Chen XF **L-Editor:** Filipodia **P-Editor:** Li JH


**Figure Legends**



**Figure 1** **Ocular assessments of the proband.** A: Fundus photo of the right and left eye; B: Ocular coherence tomography-retinal nerve fiber layer of both eyes (Key: S: Superior; T: Temporal; N: Nasal; I: Inferior); C: Right and left nasal step visual field defects consistent with glaucomatous damage.



**Figure 2** **Coinheritance of *OLFM2* and *SIX6* variants might be associated with juvenile-onset primary open-angle glaucoma.** A: The proband coinherited *OLFM2* and *SIX6* variants, indicated with a black arrow. The square represents male, circle represents female, and affected individual was shown by a filled symbol; B: The Sanger sequencing DNA chromatograms of *OLFM2* and *SIX6* for the proband and unaffected family members. The mutated nucleotides are marked with red arrows.



**Figure 3** **Evolutionary conservation of amino acids for the p.(Arg94His) and p.(Ile59Met) mutations.** A: Schematics of the functional domains of the Olfm2 and Six6 proteins and locations of the corresponding mutations; B and C: The mutation and wild type residues for *OLFM2* p.Arg94 (B) and *SIX6* p.Ile59 (C) were highlighted with a red box. Noelin-1: Neurogenesis glycoprotein domain; OLF: Olfactomedin-like domain; SIX1\_SD: Transcriptional regulator, SIX1, N-terminal SD domain; homeodomain: DNA binding domain, involved in the transcriptional regulation of key eukaryotic developmental processes.

**Table 1 Primer sequences used for Sanger sequencing**

|  |  |  |
| --- | --- | --- |
| **Gene** | **Sequence, 5’-3’** | **Product size in bp** |
| *OLFM2* | F: CGTCGGTGTGGTGTTTGTAC | 372 |
| R: TGTGGCTCATATTGGACCCT |
| *SIX6* | F: AATCCGCCTCATCAACAAGC | 825 |
| R: CAGAACGCAGGGCTCTTAAC |

F: Forward; R: Reverse.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**